More patients receiving panitumumab + FOLFOX4 versus FOLFOX4 had 30 % ( 59 % versus 38 % ; P < 0.001 ) or 20 % ( 72 % versus 57 % ; P < 0.001 ) TS at week 8 ( early TS ) ; consistent TS benefits were observed over the first 40weeks of treatment .